| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | — |
| Gross profit | 0.0 | — |
| Net income | -2.8 | -1.7 |
| EPS (diluted, $ a share) | $-0.55 | $-1.65 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Gross margin | 54.1% |
|---|
10-Q filed with the SEC, NASDAQ: DRMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dermata Therapeutics, Inc.: key numbers
- Share price
- $0.5985Close, Nov 16
- Market cap
- $2.95M
- Shares outstanding
- 4.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dermata Therapeutics, Inc.
All →Dermata Therapeutics Business Update
Dermata Therapeutics released additional results and photos from its recently completed cosmetic clinical study of Tome Foundational Treatment. The company also announced it has received over 1,000 orders for the skin renewal treatment since its recent commercial launch.
Dermata Therapeutics Financial Results
Dermata Therapeutics reported financial results for the third quarter of 2026, highlighting its transition to a revenue-generating company following the August 2025 launch of Tome Foundational Treatment. The company reported its first product revenue and noted that approximately 30% of orders were generated via subscriptions.
- Term
- Q3 2026
“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business.”
Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer
“With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder.”
Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer
Dermata Therapeutics Business Update
Dermata Therapeutics announced the enrollment of the first participant in a clinical trial for Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch this product commercially in the first half of 2027 as part of its strategic shift toward skincare products.